Here, the applicability of the NFATc1 amplification assay is tested for the first time in whole-blood samples of TAC-treated kidney transplant recipients and we explored whether this method can be translated to daily clinical practice and can be an additional tool for monitoring the effects of TAC in different T cell subsets. Here, NFATC1 is linked to urogenital neoplasm.